Systemic lupus erythematosus – when to treat with anifrolumab?

Read full text Summarise with VIRAT
Authors: P.I. Novikov, N. Bulanov, V.A. Pugach, Mariia A. Litvinova, O. Filonenko, В. В. Рамеев, S. Moiseev
Cited by: 0
References: 30

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Anifrolumab is a fully human IgG1 monoclonal antibody that binds to subunit 1 of the type I interferon (IFN) receptor and inhibits the signaling of all type I IFNs. Anifrolumab is indicated as an add-on therapy for adult patients with moderate to severe systemic lupus erythematosus (SLE) who do not respond to standard treatment. The authors report two patients with SLE successfully treated with anifrolumab and review its role in the immunosuppresive therapy for the disease.

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Systemic Sclerosis and Related Diseases Rheumatoid Arthritis Research and Therapies

Publication details

Journal / source
Clinical pharmacology and therapy
Volume
35
Issue
1
Pages
56–64
Publication date
13 February 2026
Language
EN